Getting to Target Safely: Newer long-acting basal insulin analogues for managing type 2 diabetes (T2D) – Ordre des pharmaciens du Québec (OPQ)

After completion of the program, participants will be able to:

1. Define the key targets for patients with type 2 diabetes;
2. Address misconceptions around hypoglycemia in patients with type 2 diabetes taking insulin;
3. Describe the general characteristics of long acting/ultra long acting basal insulins.
4. Discuss the ability of newer long-acting insulins, to control blood glucose in type 2 diabetes and their impact on the risk for hypoglycemia.